Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.
Develops base-editing gene therapies that precisely rewrite single DNA letters to treat genetic diseases.
Has no approved product, so its income is collaboration payments and money raised from investors, not sales. Value rests on moving its first treatments, such as BEAM-101 for sickle cell disease, through clinical trials. It also has research partnerships with larger drugmakers that pay upfront and milestone fees.
Moat: narrow (IP / patents, process know-how). Proprietary base-editing technology, more precise than CRISPR cutting, with broad foundational patents.
Headquarters: Cambridge, Massachusetts, US · Founded: 2017 · Employees: 511
Size Beam Therapeutics (BEAM) is a United States Health Care company (Biotechnology) with a market value of $2.17B, the 1723rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $21.01 on 18 Nov 2026.
Performance Over six months the shares fell 22.5%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 163.3% over the last twelve months (peer median +0.3%); the operating margin is -267.7% (peer median -15.4%).
Valuation It trades at 9.4× enterprise value to sales against a peer median of 9.8× (7th cheapest of 15).
Short interest Short interest is 25.2% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $147M | $140M | $63.5M | $378M | $60.9M |
| Revenue growth | — | +120% | -83% | +520% | — |
| Gross profit | $125M | $117M | $41.6M | $358M | $38.3M |
| EBITDA | -$370M | -$361M | -$394M | -$156M | -$316M |
| Net income | -$107M | -$80.0M | -$377M | -$133M | -$289M |
| Free cash flow | -$398M | -$360M | -$356M | -$183M | -$26.4M |
| Capital expenditure | $9.59M | $14.9M | $8.95M | $33.7M | $49.0M |
| Total debt | $244M | $154M | $161M | $173M | $182M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Beam Therapeutics BEAM | $2.17B | -22% | +163% | -268% | 9.4× | n/a |
| Intellia Therapeutics NTLA | $1.37B | -20% | -8% | -821% | 21.3× | n/a |
| CRISPR Therapeutics CRSP | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a |
| Editas Medicine EDIT | n/a | -32% | n/a | n/a | n/a | n/a |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BEAM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.7% | -4.9% | 6th lowest of 21 |
| 6-month return | -22.5% | -10.8% | 6th lowest of 20 |
| Distance from 52-week high | -45.1% | -34.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +163.3% | +0.3% | 3rd highest of 17 |
| Operating margin | -267.7% | -15.4% | 3rd lowest of 15 |
| EV / Sales | 9.4× | 9.8× | 7th cheapest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |